High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer
暂无分享,去创建一个
Antonio Marchetti | Renato Mariani-Costantini | A. Marchetti | R. Mariani-Costantini | P. Battista | E. Podesta | S. Malatesta | A. Solano | G. Aceto | M. I. Neuman | S. Veschi | A. Morgano | R. Chacón | C. Pupareli | M. Lombardi | Sara Malatesta | Gitana Maria Aceto | Angela Rosaria Solano | Maria Isabel Neuman | Serena Veschi | Annalisa Morgano | Reinaldo Daniel Chacon | Carmen Pupareli | Mercedes Lombardi | Pasquale Battista | Ernesto Jorge Podestà
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Levine,et al. Increasing evidence for a human breast carcinoma virus with geographic differences , 2004, Cancer.
[3] Jens Overgaard,et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Wisell. Most basal-like breast carcinomas demonstrate the same Rb−/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically , 2010 .
[5] C. Balch,et al. AJCC Cancer Staging Manual. 6th ed , 2002 .
[6] H. Bartsch,et al. IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation. , 1992, IARC monographs on the evaluation of carcinogenic risks to humans.
[7] M J Gaffey,et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. , 1995, American journal of clinical pathology.
[8] Kenneth Offit,et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. , 2003, Journal of the National Cancer Institute.
[9] M. Aoki,et al. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. , 2009, International journal of molecular medicine.
[10] W. Sterry,et al. Human Papillomavirus and Overexpression of P16INK4a in Nonmelanoma Skin Cancer , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[11] P. Oefner,et al. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. , 1999, Genomics.
[12] M. Stanley. Chapter 17: Genital human papillomavirus infections--current and prospective therapies. , 2003, Journal of the National Cancer Institute. Monographs.
[13] Albert Koong,et al. Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.
[14] K. Deschryver,et al. Pathology of the breast in children, adolescents, and young adults. , 1999, Seminars in diagnostic pathology.
[15] D. Lowy,et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer , 2008, Cancer.
[16] C. Hsieh,et al. Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[17] B. Morris. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region , 2005, Clinical chemistry and laboratory medicine.
[18] M. Stoler,et al. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[19] R. Malekzadeh,et al. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K‐ras mutations , 2008, Journal of cellular physiology.
[20] R. Mariani-Costantini,et al. High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] R. Mariani-Costantini,et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. , 2003, Cancer research.
[22] D. Pim,et al. Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.
[23] D. Spandidos,et al. Human papilloma virus (HPV) infection in children and adolescents , 2009, European Journal of Pediatrics.
[24] M. von Knebel Doeberitz,et al. Detection of integrated papillomavirus sequences by ligation‐mediated PCR (DIPS‐PCR) and molecular characterization in cervical cancer cells , 2001, International journal of cancer.
[25] C. Woodman,et al. The natural history of cervical HPV infection: unresolved issues , 2007, Nature Reviews Cancer.
[26] M. von Knebel Doeberitz,et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. , 2005, Journal of the National Cancer Institute.
[27] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[28] I. Frazer,et al. Development of therapeutic HPV vaccines. , 2009, The Lancet. Oncology.
[29] Jahn M. Nesland,et al. Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). , 2004, Breast Cancer Research and Treatment.
[30] E. McDermott,et al. Pregnancy-associated breast cancer. , 2002, Irish medical journal.
[31] O. Yamanoshita,et al. DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues , 2005, International journal of cancer.
[32] Andrew Shenton,et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. , 2006, European journal of cancer.
[33] T. Soussi. The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.
[34] P. Lambert,et al. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[35] B. Henderson,et al. Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-Based Study , 2008, Cancer Epidemiology Biomarkers & Prevention.
[36] N. Muñoz,et al. HPV in the etiology of human cancer , 2006 .
[37] L. Laimins,et al. Human papillomaviruses and the interferon response. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[38] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[39] M. von Knebel Doeberitz,et al. Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri , 2001, International journal of cancer.
[40] V. Moreno,et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study , 2002, The Lancet.
[41] J. Russo,et al. Role of Hormones in Mammary Cancer Initiation and Progression , 2004, Journal of Mammary Gland Biology and Neoplasia.
[42] H. Rice,et al. Juvenile papillomatosis of the breast in male infants: two case reports , 2000, Pediatric Surgery International.
[43] K. Nathanson,et al. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women , 2005, Genetics in Medicine.
[44] H. Pitot,et al. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. , 2008, Cancer research.
[45] G. Schwartsmann. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] P. Rosen. Rosen's Breast Pathology , 2001 .
[47] S. Narod. Modifiers of risk of hereditary breast cancer , 2006, Oncogene.
[48] B. Hulka,et al. Breast cancer: hormones and other risk factors. , 2001, Maturitas.
[49] Jinhua Wang,et al. ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..
[50] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] K. Nathanson,et al. Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic , 2006, Cancer biology & therapy.
[52] R. Mariani-Costantini,et al. BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors , 2007, Breast Cancer Research and Treatment.
[53] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[54] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[55] Christos Kroupis,et al. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. , 2006, Clinical biochemistry.
[56] J. Benítez,et al. The Molecular Pathology of Hereditary Breast Cancer , 2008, Pathobiology.
[57] R. Mariani-Costantini,et al. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. , 1997, Cancer research.
[58] Y. Hiraku,et al. Catechol estrogens induce oxidative DNA damage and estradiol enhances cell proliferation , 2001, International journal of cancer.
[59] G. Tortolero-Luna,et al. Human papillomavirus infection: biology, epidemiology, and prevention , 2005, International Journal of Gynecologic Cancer.
[60] W. Dinjens,et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8 , 2003, International journal of cancer.
[61] C. la Vecchia,et al. Attributable risks for breast cancer in Italy: Education, family history and reproductive and hormonal factors , 1997, International journal of cancer.
[62] J. Chang-Claude,et al. Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women. , 1998, American journal of obstetrics and gynecology.
[63] Niladri Ganguly,et al. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis , 2009, Journal of Biosciences.
[64] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[65] S. Vinokurova,et al. Systematic Review of Genomic Integration Sites of Human Papillomavirus Genomes in Epithelial Dysplasia and Invasive Cancer of the Female Lower Genital Tract , 2004, Cancer Research.
[66] H. Dienes,et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. , 2003, The American journal of pathology.
[67] Blossom Damania,et al. Infectious agents and cancer: criteria for a causal relation. , 2004, Seminars in cancer biology.
[68] Y. Ye,et al. Human papilloma virus is associated with breast cancer , 2009, British Journal of Cancer.
[69] W. Willett,et al. Diet, body size, and breast cancer. , 1993, Epidemiologic reviews.
[70] V. Band,et al. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[71] E. Speel,et al. Genetic Signatures of HPV-related and Unrelated Oropharyngeal Carcinoma and Their Prognostic Implications , 2009, Clinical Cancer Research.
[72] J. Russo,et al. The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention. , 2006, Frontiers in bioscience : a journal and virtual library.
[73] R. Dumitrescu,et al. Understanding breast cancer risk ‐ where do we stand in 2005? , 2005, Journal of cellular and molecular medicine.
[74] Charles M Perou,et al. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas , 2008, Breast Cancer Research.
[75] Xavier Castellsagué,et al. Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.
[76] D. Medina. Mammary developmental fate and breast cancer risk. , 2005, Endocrine-related cancer.
[77] T. Nakajima,et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. , 1998, The American journal of pathology.
[78] S. Henikoff,et al. Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.
[79] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[80] K. Soo,et al. Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development , 2005, Cancer Epidemiology Biomarkers & Prevention.
[81] G. Mazzini,et al. Loss of Retinoblastoma Tumor Suppressor Protein Makes Human Breast Cancer Cells More Sensitive to Antimetabolite Exposure , 2008, Clinical Cancer Research.
[82] Rachid Karam,et al. Evidence for an Association of Human Papillomavirus and Breast Carcinomas , 2004, Breast Cancer Research and Treatment.
[83] H Peng,et al. Human papillomavirus DNA is present in a subset of unselected breast cancers. , 2001, Journal of human virology.
[84] D. Pim,et al. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.
[85] A. Kaufmann,et al. Therapeutic Human Papillomavirus Vaccination , 2008, Public Health Genomics.
[86] L. Hilakivi-Clarke,et al. Fetal origins of breast cancer , 2006, Trends in Endocrinology & Metabolism.
[87] D. Lipsker,et al. p16 expression in relation to human papillomavirus in anogenital lesions. , 2006, Human pathology.
[88] G. Sakamoto,et al. Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast , 2005, Breast cancer.
[89] T. Benn. Cancer Incidence in 5 Continents, Vol. IV , 1983, British Journal of Cancer.
[90] N. S. Murthy,et al. Polymorphism of the p53 codon 72 arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India , 2003, Molecular and Cellular Biochemistry.
[91] J. Chang-Claude,et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). , 2006, Journal of the National Cancer Institute.
[92] L. Montanaro,et al. The p53‐mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein , 2009, The Journal of pathology.
[93] S. Niruthisard,et al. Human papillomavirus DNA in plasma of patients with cervical cancer , 2001, BMC Cancer.
[94] Anna Di Lonardo,et al. Human papillomavirus in breast cancer , 2005, Breast Cancer Research and Treatment.